The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Myriad Genetics, Inc. (MYGN)

NEW YORK--()--The Klein Law Firm announces the commencement of an investigation of Myriad Genetics, Inc. (NASDAQGS:MYGN) concerning possible violations of federal securities laws.

On March 12, 2018, Myriad Genetics filed an 8-K with the U.S. Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.” The subpoena requests documents related to Myriad Genetic’s “billing to government-funded healthcare programs for the Company’s hereditary cancer testing” from 2014 through the receipt of the subpoena.

If you suffered a loss in Myriad Genetics and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/MYGN-Info-Request-Form-293.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Contacts

The Klein Law Firm
Joseph Klein, Esq.
212-616-4899

Release Summary

The Klein Law Firm announces the commencement of an investigation of Myriad Genetics, Inc.

Contacts

The Klein Law Firm
Joseph Klein, Esq.
212-616-4899